RxDoctor Payments Data

John Rudolph, DO

Family Medicine · Lewiston, IDNPI 1548503022

Payments from drug & device makers

$973in general payments, 2019–2025

Across 46 payments — averaging $21.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$218
  • Astellas Pharma US Inc$168
  • Boehringer Ingelheim$82
  • Sanofi-aventis U.S. LLC$79
  • Novo Nordisk$61
  • Otsuka America Pharmaceutical, Inc.$55
  • plus $310 from 11 others

What the payments were for

  • Food & beverage$87490%
  • Education$9910%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$973 in reported general payments places this provider in the 70th percentile of 803 family medicine providers in Idaho.

See all family medicine providers in Idaho

Medicare billing

Part B allowed, 2024
$241,891
Medicare patients
890
Services billed
4,634

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban1,006$328,116
OzempicSemaglutide42$46,095
JardianceEmpagliflozin93$43,793
JanuviaSitagliptin Phosphate83$39,548
MyrbetriqMirabegron141$35,655
GlatopaGlatiramer Acetate24$32,921
TrulicityDulaglutide32$29,417
Trelegy ElliptaFluticasone/Umeclidin/Vilanter46$27,823
XareltoRivaroxaban28$21,680
RestasisCyclosporine47$20,715
Topiramate ErTopiramate12$19,899
Breo ElliptaFluticasone/Vilanterol43$19,117
Potassium Chloride571$17,958
Lantus SolostarInsulin Glargine,hum.Rec.Anlog174$13,465
Spiriva HandihalerTiotropium Bromide27$13,235

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Abrysvo$16$334,7131,027 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$27$55,006126 claims
Novo NordiskOzempic$61$46,09542 claims
Boehringer IngelheimJardiance$82$43,79393 claims
Astellas Pharma US IncMyrbetriq$168$35,655141 claims
Johnson & JohnsonXarelto, Invokana$40$29,73256 claims
Lilly USA, LLCTrulicity$42$29,41732 claims
AbbVieRestasis$218$20,71547 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 803 family medicine providers in Idaho.

Other family medicine in Lewiston

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →